The company has secured funding from the European Innovation Council (EIC) for a project to progress the company’s PeptiCHIP technology.

PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies.

Read more: Reinventing immunotherapy – Valo Therapeutics NLS Star 2022

The project, which will be fully funded by the EIC with a 100%, non-dilutive, grant is called “Pre-clinical validation and demonstration of PeptiCHIP”. ValoTx also gains access to EIC Business Acceleration Services including coaching, mentoring, and partnering events.

“I’m delighted that the EIC has chosen to support us as we develop PeptiCHIP alongside our clinical development program. Identification of relevant antigens is one of the key challenges in developing effective immunotherapies for cancer. PeptiCHIP will allow us to do exactly this for our own clinical development and for partnerships with other innovative companies. The unique adaptability and flexibility our lead platform PeptiCRAd provides, coupled with our own antigen identification by PeptiCHIP, will allow us to develop economically viable and real-world practical personalized cancer immunotherapy,” says Paul Higham, CEO of ValoTx.

Photo of Paul Higham: Teresa Walton